How to Help Your Patients Find Edarbi in Stock: A Provider's Guide

How to Help Your Patients Find Edarbi in Stock: A Provider's Guide

You've prescribed Edarbi (Azilsartan Medoxomil) because it's the right clinical choice for your patient's hypertension. But now they're calling back to say they can't find it. Their pharmacy doesn't carry it, the one across town is out, and they're running low on their current supply.

This is a frustratingly common scenario with brand-name medications that lack generic alternatives. Here's a practical guide to help you and your clinical team navigate Edarbi availability challenges and keep your patients on effective therapy.

Current Edarbi Availability

Edarbi is not in a formal FDA-listed shortage as of March 2026. The medication is manufactured by Azurity Pharmaceuticals and distributed through standard pharmaceutical wholesalers.

However, practical availability is a different matter. Because Edarbi is a brand-name ARB with no generic on the market, most pharmacies — particularly national chains — do not keep it in regular inventory. The majority of ARB prescriptions are filled with generic Losartan, Valsartan, or Olmesartan, which means Edarbi is a low-volume item that many pharmacies choose not to stock.

This doesn't mean it's unavailable — it means it requires more effort to locate and fill than a typical prescription.

Why Patients Can't Find Edarbi

Understanding the root causes helps you counsel patients and set appropriate expectations:

1. No generic alternative: Edarbi is the only Azilsartan Medoxomil product on the market. Without generic competition, supply is limited to a single manufacturer.
2. Pharmacy inventory decisions: Chain pharmacies use demand-based stocking algorithms. Low-volume brand-name drugs are deprioritized or removed from standing inventory.
3. Insurance formulary barriers: Step therapy requirements and prior authorization reduce the number of Edarbi prescriptions written, which suppresses pharmacy demand further.
4. Patient awareness gaps: Many patients don't know they can ask a pharmacist to special order a medication or search for alternate pharmacies. They interpret "we don't have it" as "it's unavailable."

For a patient-facing explanation you can share, see why Edarbi is so hard to find.

What Providers Can Do: 5 Steps

Step 1: Verify Stock Before Prescribing

The single most impactful thing you can do is confirm that Edarbi is available at the patient's pharmacy before sending the prescription. This prevents the frustrating experience of receiving a rejection or "not in stock" message after the patient has already left your office.

Tools for verification:

• Medfinder for Providers — Search for pharmacies near your patient that currently have Edarbi in stock
• Direct phone call to the pharmacy
• Patient portal or e-prescribing system notifications (if available)

Step 2: Route Prescriptions to Stocking Pharmacies

If the patient's usual pharmacy doesn't carry Edarbi, help them identify one that does. Options include:

• Independent pharmacies — More likely to accommodate special orders and brand-name medications
• Specialty pharmacies — Some focus on cardiovascular or chronic disease medications
• Mail-order pharmacies — Can ship Edarbi directly to the patient's home

Use Medfinder to identify nearby options in real time.

Step 3: Write for 90-Day Supplies When Possible

A 90-day prescription reduces refill frequency from 12 times per year to 4, cutting the number of pharmacy interactions and opportunities for stockout issues. It also gives the pharmacy more predictability for ordering.

This is especially helpful for patients using mail-order pharmacy, where 90-day supplies are standard.

Step 4: Support Prior Authorization Proactively

If the patient's insurance requires prior authorization or step therapy, proactive documentation streamlines the process:

• Document previous ARB trials (drug, dose, duration, response)
• Note specific tolerability issues with alternatives
• Reference clinical trial data showing Edarbi's superior blood pressure reduction compared to Olmesartan and Valsartan
• Submit the prior authorization before or at the time of prescribing, not after the pharmacy rejects the claim

Step 5: Educate the Patient

Empower patients with information and tools:

• Explain that Edarbi may not be stocked at all pharmacies, but it can be ordered
• Share Medfinder as a resource for finding pharmacies with stock
• Inform them about the Azurity Solutions E-Z Rx copay card ($15/month with commercial insurance)
• Provide our patient guide: How to Find Edarbi in Stock Near You

Clinical Alternatives to Edarbi

When Edarbi access is consistently problematic, transitioning to a generic ARB may be the most practical solution. Here are the most commonly considered alternatives:

MedicationTypical DoseMonthly Generic CostKey NotesLosartan (Cozaar)25-100 mg daily$4-$15Most widely prescribed ARB; also indicated for diabetic nephropathy and stroke preventionValsartan (Diovan)80-320 mg daily$10-$20Strong evidence for heart failure and post-MI; widely availableOlmesartan (Benicar)20-40 mg daily$10-$25Closest potency to Edarbi; rare risk of sprue-like enteropathyTelmisartan (Micardis)20-80 mg daily$10-$20Longest half-life among ARBs; cardiovascular risk reduction data from ONTARGET

For a patient-facing comparison, see alternatives to Edarbi.

Workflow Tips for Your Practice

Integrating these strategies into your clinical workflow can reduce patient callbacks and improve medication adherence:

• Add a pharmacy verification step to your prescribing workflow for Edarbi and other brand-name-only medications
• Create a staff resource with the Medfinder link (medfinder.com/providers) and the Azurity copay card details for quick reference
• Use EHR templates to pre-populate prior authorization language for Edarbi when documenting hypertension visits
• Flag Edarbi patients in your practice management system so staff can proactively check availability at refill time
• Stock patient handouts — Print or share links to our patient resources on finding Edarbi and saving money on Edarbi

Final Thoughts

Edarbi is a clinically effective ARB that fills an important niche for patients who need more potent blood pressure reduction than generic alternatives provide. The availability challenges are real but manageable with the right approach.

By verifying stock before prescribing, routing prescriptions to pharmacies that carry Edarbi, supporting prior authorizations proactively, and educating patients about their options, you can minimize disruptions and keep your patients on the therapy that works best for them.

Visit Medfinder for Providers to start checking pharmacy availability for your patients today.